Characterization of Herpes Simplex Virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity
- 1 September 2002
- journal article
- Published by Wiley in Protein Science
- Vol. 11 (9), 2267-2272
- https://doi.org/10.1110/ps.2460102
Abstract
Herpes Simplex Virus type 1 (HSV-1) thymidine kinase (TK) is currently the most widely used suicide agent for gene therapy of cancer. Tumor cells that express HSV-1 thymidine kinase are rendered sensitive to prodrugs due to preferential phosphorylation by this enzyme. Although ganciclovir (GCV) is the prodrug of choice for use with TK, this approach is limited in part by the toxicity of this prodrug. From a random mutagenesis library, seven thymidine kinase variants containing multiple amino acid substitutions were identified on the basis of activity towards ganciclovir and acyclovir based on negative selection in Escherichia coli. Using a novel affinity chromatography column, three mutant enzymes and the wild-type TK were purified to homogeneity and their kinetic parameters for thymidine, ganciclovir, and acyclovir determined. With ganciclovir as the substrate, one mutant (mutant SR39) demonstrated a 14-fold decrease in K(m) compared to the wild-type enzyme. The most dramatic change is displayed by mutant SR26, with a 124-fold decrease in K(m) with acyclovir as the substrate. Such new "prodrug kinases" could provide benefit to ablative gene therapy by now making it feasible to use the relatively nontoxic acyclovir at nanomolar concentrations or ganciclovir at lower, less immunosuppressive doses.Keywords
This publication has 32 references indexed in Scilit:
- Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutantGene Therapy, 1999
- Effect on substrate binding of an alteration at the conserved aspartic acid-162 in herpes simplex virus type 1 thymidine kinaseJournal of General Virology, 1996
- The “Bystander Effect”: Association of U-87 Cell Death with Ganciclovir-Mediated Apoptosis of Nearby Cells and Lack of Effect in Athymic MiceHuman Gene Therapy, 1995
- Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection.Proceedings of the National Academy of Sciences of the United States of America, 1994
- In VitroEvidence That Metabolic Cooperation Is Responsible for the Bystander Effect Observed with HSVtkRetroviral Gene TherapyHuman Gene Therapy, 1993
- Regression of established macroscopic liver metastases after in situ transduction of a suicide gene.Proceedings of the National Academy of Sciences of the United States of America, 1993
- Viral thymidine kinases and their relativesPharmacology & Therapeutics, 1992
- In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain TumorsScience, 1992
- Herpesviral Deoxythymidine Kinases Contain a Site Analogous to the Phosphoryl-binding Arginine-rich Region of Porcine Adenylate Kinase; Comparison of Secondary Structure Predictions and ConservationJournal of General Virology, 1990
- Cell-free synthesis of enzymatically active vaccinia virus thymidine kinaseVirology, 1981